Patents by Inventor Ming-Jiu Chen

Ming-Jiu Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic DLL4 Binding Proteins
    Publication number: 20210009681
    Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.
    Type: Application
    Filed: February 7, 2020
    Publication date: January 14, 2021
    Applicant: AbbVie Inc.
    Inventors: Ming-Jiu Chen, Chung-Ming Hsieh, Jije Gu, Susan Morgan-Lappe, Yingchun Li
  • Therapeutic DLL4 Binding Proteins
    Publication number: 20190315855
    Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.
    Type: Application
    Filed: April 28, 2017
    Publication date: October 17, 2019
    Applicant: AbbVie Inc.
    Inventors: Ming-Jiu Chen, Chung-Ming Hsieh, Jije Gu, Susan Morgan-Lappe, Yingchun Li
  • Therapeutic DLL4 binding proteins
    Patent number: 9469689
    Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: October 18, 2016
    Assignee: AbbVie Inc.
    Inventors: Ming-Jiu Chen, Chung-Ming Hsieh, Jijie Gu, Susan E. Morgan-Lappe, Yingchun Li
  • Therapeutic DLL4 Binding Proteins
    Publication number: 20160031986
    Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.
    Type: Application
    Filed: July 14, 2015
    Publication date: February 4, 2016
    Inventors: Ming-Jiu CHEN, Chung-Ming HSIEH, Jijie GU, Susan E. MORGAN-LAPPE, Yingchun LI
  • Therapeutic DLL4 binding proteins
    Patent number: 9115195
    Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: August 25, 2015
    Assignee: ABBVIE INC.
    Inventors: Ming-Jiu Chen, Chung-Ming Hsieh, Jijie Gu, Susan E. Morgan-Lappe, Yingchun Li
  • THERAPEUTIC DLL4 BINDING PROTEINS
    Publication number: 20110217237
    Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.
    Type: Application
    Filed: March 1, 2011
    Publication date: September 8, 2011
    Applicant: ABBOTT LABORATORIES
    Inventors: Ming-Jiu Chen, Chung-Ming Hsieh, Jijie Gu, Susan E. Morgan-Lappe, Yingchun Li